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A B S T R A C T   
The NF-ĸB transcription factor is a critical regulator of immune homeostasis and inflammatory responses and is a critical factor in the pathogenesis of inflammatory 
disease. The pathways to NF-ĸB activation are paradigms for signal-induced ubiquitination and proteasomal degradation, control of transcription factor function by 
subcellular localisation, and the control of gene transcription and physiological processes by signal transduction mechanisms. Despite the importance of NF-ĸB in 
disease, the NF-ĸB pathway remains unexploited for the treatment of inflammatory disease. Our understanding of NF-ĸB comes mostly from studies of transgenic 
mice and cell lines where components of the pathway have been deleted or over expressed. Recent advances in quantitative proteomics offer new opportunities to 
understand the NF-ĸB pathway using the absolute abundance of individual pathway components. We have analysed available quantitative proteomic datasets to 
establish the structure of the NF-ĸB pathway in human immune cells under both steady state and activated conditions. This reveals a conserved NF-κB pathway 
structure across different immune cell lineages and identifies important differences to the current model of the NF-ĸB pathway. These include the findings that the 
IKK complex in most cells is likely to consist predominantly of IKKβ homodimers, that the relative abundancies of IκB proteins show strong cell type variation, and 
that the components of the non-canonical NF-ĸB pathway are significantly increased in activated immune cells. These findings challenge aspects of our current view 
of the NF-κB pathway and identify outstanding questions important for defining the role of key components in regulating inflammation and immunity.   
1. Introduction 
Since its discovery over 30 years ago, NF-κB has served as a model for 
inducible transcription factors, signal-directed ubiquitination, and the 
impact of signal transduction pathways on gene expression and physi-
ological processes [1]. The NF-ĸB transcription factor is a master regu-
lator of inflammation and immunity, and a key factor in the pathology of 
diseases responsible for the majority of deaths worldwide [2]. As such, 
NF-κB and the pathways that lead to its activation are important targets 
that have yet to be harnessed for therapeutic benefit. 
NF-κB is in fact a family of transcription factors composed of the p65 
(RelA), c-Rel, RelB, p50 and p52 subunits that form both homodimers 
and heterodimers [3]. The p50 and p52 subunits share two key prop-
erties that distinguish them from other subunits; the absence of a 
transactivation domain and their formation through the limited pro-
teasomal processing of the precursor proteins p105 (NFKB1) and p100 
(NFKB2) which generate p50 and p52 respectively [3]. In the steady 
state, NF-κB dimers are sequestered in the cytoplasm through interac-
tion with the IκB family of proteins that include IκBα, IκBβ and IκBε [4]. 
Also included in this family of NF-κB inhibitory proteins are the p105 
and p100 precursor proteins which sequester NF-κB dimers in via a C 
terminal ankyrin repeat domain homologous to the central ankyrin 
repeat domains found in IκBα, IκBβ and IκBε [4]. 
The IKK complex is required for NF-κB activation in response to the 
majority of immunoreceptors in what is termed the classical NF-κB 
pathway [3]. The IKK complex is composed of the homologous IKKα and 
IKKβ kinases bound to the scaffold protein NEMO [5]. Activation of NF- 
κB follows activation of the IKK complex which phosphorylates IκB 
proteins, triggering their polyubiquitination and subsequent proteaso-
mal degradation, liberating NF-κB dimers which then translocate to the 
nucleus [3]. A second, evolutionarily conserved pathway for the acti-
vation of NF-κB is triggered in response to a limited number of TNF 
receptor superfamily members including BAFF receptor, lymphotoxin β 
receptor, RANK and CD40 [6]. This alternative pathway requires IKKα, 
but not NEMO nor IKKβ, which phosphorylates p100 leading to its 
polyubiquitination and subsequent proteasomal degradation. These 
events lead to the nuclear translocation of NF-κB dimers composed of the 
RelB and p52 subunits [7]. A negative feedback loop involving the NF- 
κB-dependent induction of IκB gene expression is the predominant 
mechanism for terminating NF-κB activity. Newly synthesised IκB pro-
teins translocate to the nucleus where they bind NF-κB dimers and 
mediate their export from the nucleus. Importantly, the degradation and 
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stimulus-induced expression profile of each IκB subunit appears distinct 
and may be linked to a specific role for each protein in regulating 
inflammation. The rapid degradation and resynthesis of IκBα allows for 
the rapid inhibition of NF-κB activity while the slower kinetics of IκBβ 
and IκBε degradation may act to dampen long-term oscillations of the 
NF-κB response [4]. 
Post-activation, NF-κB is subject to a complex network of post 
translational modifications, pre-dominantly phosphorylation and ubiq-
uitination, which serve to regulate DNA binding affinity, transactivation 
activity and protein stability [8,9]. Phosphorylation of NF-κB subunits 
occurs at numerous sites and can regulate transcription in a gene se-
lective manner [8], while NF-κB ubiquitination is an important mech-
anism for terminating transcriptional activity [9]. Activated NF-κB 
dimers are also regulated by atypical members of the IκB family of 
proteins which include BCL-3, IκBζ, IκBNS and IκBη. These proteins are 
predominantly nuclear in localisation and are not degraded following 
IKK activation [4]. Rather, they serve to modulate the function of NF-κB 
dimers in the nucleus by enhancing or inhibiting NF-κB transcriptional 
activity. Similar to the typical IκB proteins the atypical IκB proteins 
show selectivity in binding to specific NF-κB dimers [4]. 
The importance of NF-κB in physiological and pathological process 
has been largely informed by studies of transgenic mice deficient in core 
components of the NF-κB pathway [10]. The accepted model of the NF- 
κB pathway is based on biochemical and molecular biology studies often 
involving overexpression of factors in cell lines or analysis of trans-
formed mouse embryonic fibroblasts derived from transgenic mice. 
Recent advances in quantitative proteomics present new opportunities 
to define the structure and composition of the NF-κB pathway. 
Here, we analyse publicly available quantitative proteomic data to 
generate a model of the NF-κB pathway based on the stoichiometry and 
abundance of individual components in primary human immune cells 
[11]. This analysis demonstrates a remarkable conservation of the 
structure and abundance of the NF-κB pathway across different immune 
cell lineages. It suggests that the composition of the IKK complex in most 
cells is likely to consist of IKKβ homodimers, and reveals an unexpected 
variation in the relative abundancies of IκBα, IκBβ and IκBε in different 
cell types, indicating cell type specific roles. In most cell types, stimu-
lation results in a significant increase in the levels of the RelB and p100 
subunits suggesting that the non-canonical pathway plays an important 
role in activated immune cells. These findings challenge aspects of our 
current view of the NF-κB pathway and identify outstanding questions 
important for defining the role of key components in regulating 
inflammation and immunity. 
2. Materials and methods 
2.1. Datasets and analysis 
Proteomic data was sourced from the published studies in references 
[11–14]. Networks were generated using Cytoscape. Hierarchical clus-
tering and similarity matrix generation was performed using Morpheus 
(https://software.broadinstitute.org/morpheus). 
2.2. CD14+ monocyte isolation and stimulation 
Peripheral blood mononuclear cells (PBMCs) were isolated from 
fresh blood of healthy donors by density gradient. Blood was diluted 1:1 
in sterile phosphate-buffered saline (PBS; Gibco, UK), carefully applied 
to 3 ml of Ficoll-Paque Plus (Cytiva, UK) and layered by centrifuging at 
400g for 30 min with no brakes. The top layer (plasma) was discarded 
and the layer beneath containing PBMCs was collected. PBMCs were 
washed three times in PBS and centrifuged at 300g for 10 min between 
the washes. CD14+ monocytes were isolated from PBMCs with EasySep 
Human CD14 Positive Selection kit according to the manufacturer’s 
instructions (Stemcell Technologies, UK). The isolated monocytes were 
subsequently resuspended at 1 × 106 cells/ml in complete Alpha Mini-
mum Essential Medium (α-MEM; Gibco, UK) supplemented with 10% 
fetal bovine serum (FBS), 1% penicillin/streptomycin and 1% L- 
Fig. 1. The NF-κB pathway. Schematic overview of the NF-ĸB pathway and its component factors (A) and (B) the proteomic data from human primary cell types 
from [11] analysed. CD4, CD4+ T cells; CD4 CM, CD4+ central memory T cells; CD4 EM, CD4+ effector memory T cells; CD4 EMRA, CD4+CD45+ effector memory T 
cells; CD8, CD8+ T cells; T reg, regulatory T cells; NK bright, natural killer cells CD56high; NK dim, natural killer cells CD56low; MO classical, monocytes 
CD14+CD16− ; MO intermediate, monocytes CD14+CD16low; MO non-classical, monocytes CD14+CD16+; mDC, myeloid dendritic cells; pDCs, plasmacytoid dendritic 
cells. Interactions are indicated by black lines; phosphorylation by dashed purple lines; and inhibition by blue lines. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web version of this article.) 
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glutamine. Cells were stimulated with 100 ng/ml LPS (Escherichia coli 
055:B5, Sigma, UK) for 16 h prior to analysis by western blotting. 
2.3. Western blotting 
Whole cell lysates were prepared from cells previously washed twice 
in ice-cold PBS and suspended in RIPA buffer containing 50 mM Tris-HCl 
pH 7.4, 1% NP-40, 0.25% deoxycholate, 150 mM NaCl, 1 mM EDTA, 
supplemented with 1 mM PMSF, 1 mM NaF, 1 mM Na3VO4, 2 μg/ml 
aprotinin, 1 μg/ml pepstatin and 1 μg/ml leupeptin. Lysates were 
resolved using Tris-Glycine SDS PAGE, transferred to nitrocellulose 
membranes and immunoblotted with specific antibodies. Anti-p105/ 
p50 (HPA027305) and anti p100/p52 (HPA008422) were obtained 
from Atlas Antibodies. Anti-cRel (sc-71) and anti-RelB (sc-226) were 
obtained from Santa Cruz Biotechnology. Anti-p65 (A301-824A) was 
obtained from Bethyl Laboratories. Anti-α-tubulin antibody (T6074) was 
purchased from Sigma. Western blots were imaged using a digital 
chemiluminescence scanner (LiCor). 
3. Results 
To determine the structure of the NF-κB pathway in human immune 
cells we analysed the quantitative proteomic dataset recently generated 
by Reickman and colleagues [11]. We defined the NF-κB pathway as the 
IKK complex (NEMO, IKKα and IKKβ), the IκB factors (IκBα, IκBβ, IκBε, 
p105 and p100), the NF-κB subunits (RelA/p65, c-Rel, p50, p52 and 
RelB) and the atypical IκB factors (IκBNS, IκBζ and BCL-3) (Fig. 1A). 
Data on these proteins from lymphoid and myeloid cells at the steady 
state and following activation were used for the analysis carried out here 
(Fig. 1B). 
3.1. Composition of the IKK complex 
The IKK complex is a tripartite complex composed of the homologous 
kinases IKKα and IKKβ, and the scaffold protein NEMO [15,16] (Fig. 2A). 
Although the IKK complex is essential for the activation of NF-ĸB by 
most stimuli, the stoichiometry of IKKα, IKKβ and NEMO remains to be 
conclusively defined. A ratio of IKKα1:IKKβ1:NEMO2 has been recently 
proposed based on crystallographic and quantitative analyses of the 
interaction between N-terminal NEMO and C-terminal IKK fragments 
[17] and reconstitution of the IKK complex in yeast [18]. Here, analysis 
of IKK component copy numbers across all immune cell types reveals 
that IKKβ is the most abundant component of the IKK complex, followed 
by NEMO and IKKα, which is a relatively minor component by abun-
dance (Fig. 2B). This pattern of relative abundance is typified in CD4+ T 
cells, naïve B cells, monocytes and myeloid dendritic cells (mDCs) 
(Fig. 2C). Calculating the ratio of IKKα/β:NEMO across all cell types 
indicates that the overall average ratio of IKKs to NEMO is 2:1 (Fig. 2D). 
Assuming all NEMO is bound to IKK proteins these data suggest that the 
most likely stoichiometry of the IKK complex is (IKKα/β)2:NEMO1. 
Alternatively, the proposed (IKKα/β)2:NEMO2 configuration would 
require the presence of significant pools of IKKs unbound by NEMO. This 
analysis also reveals that the majority of IKK complexes are composed of 
IKKβ homodimers, assuming all IKKs are dimerised. In addition, there is 
significant variation in IKKα/β:NEMO ratios across cell types which 
suggests that the composition of the IKK complex may vary in different 
Fig. 2. Stoichiometry of the IKK complex in different human primary immune cell types at the steady state. (A) The IKK complex is formed from the IKKα and 
IKKβ kinases, and the NEMO scaffold protein. (B) The steady state copy number per cell of IKKα, IKKβ and NEMO for all cell types. The mean value of replicate 
samples for each cell type is presented. Violin plot shows upper and lower quartiles (dotted lines), and the median (solid line). (C) Copy number per cell at the steady 
state of IKKα, IKKβ and NEMO for CD4+ T cells, naïve B cells, monocytes (classical monocytes) and myeloid DCs (mDC). Individual replicate values are shown, mean 
value is indicated by solid line, boxes extend from the upper to lower quartile and whiskers indicate minimum and maximum values. (D) Average ratios of IKKα and 
IKKβ to NEMO at the steady state for all cell types. Violin plot shows upper and lower quartiles (dotted lines) and the median (solid line). (E) The ratio of IKKα and 
IKKβ (IKK) to NEMO copy number for individual cell types at the steady state. Individual replicate values are shown, median value is indicated by solid line, boxes 
extend from the upper to lower quartile, and whiskers indicate minimum and maximum values. CD4, CD4+ T cells; CD4 CM, CD4+ central memory T cells; CD4 EM, 
CD4+ effector memory T cells; CD4 EMRA, CD4+CD45+ effector memory T cells; CD8, CD8+ T cells; T reg, regulatory T cells; NK bright, natural killer cells CD56high; 
NK dim, natural killer cells CD56low; MO classical, monocytes CD14+CD16− ; MO intermediate, monocytes CD14+CD16low; MO non-classical, monocytes 
CD14+CD16+; pDCs, plasmacytoid dendritic cells. 
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cells (Fig. 2E). For example, the relative abundancies of the IKK com-
ponents in CD4+ T cells (IKKα/β:NEMO 2.87 ± 0.32) would allow an IKK 
complex composed entirely of IKKβ and NEMO alongside free IKKα. In 
contrast, neutrophils appear to have by far the lowest ratio of IKKα/β: 
NEMO (0.54 ± 0.26) suggesting that there are significant amounts of 
NEMO not bound to IKKs in these cells. Much of the previous work on 
the composition of the IKK complex has come from studies involving cell 
lines such as HeLa [5]. Analysis of available quantitative proteomic data 
from HeLa cells [12,13] shows that these cells have a strikingly different 
profile of IKKα, IKKβ and NEMO abundances unlike any of the immune 
cell types analysed here. These data show that the levels of IKKα and 
IKKβ in HeLa cells are equivalent to one another and are 2–3 times lower 
than those of NEMO (Supplementary Fig. 1). What influence different 
abundancies of IKK complex constituents may have on the stoichiometry 
and function of the IKK complex however, is not clear. 
3.2. The IĸB family of proteins show cell type specific patterns of 
abundance 
IĸBα, IĸBβ and IĸBε are the proto-typical IĸB proteins that sequester 
NF-ĸB dimers in the cytoplasm of resting cells and undergo signal- 
induced phosphorylation, degradation and re-synthesis to control NF- 
ĸB transcriptional activity [4]. There is a wide distribution of IĸBα, IĸBβ 
and IĸBε protein levels across all cell types (Fig. 3A), however the total 
number of IĸB proteins per cell is less variable (Fig. 3B). In the majority 
of cells, including CD8+ T cells, IĸBβ is the most highly expressed IĸB 
protein (Fig. 3A and Supplementary Fig. 2) (Fig. 3C). However, there are 
distinct patterns of IĸB protein abundancies found in different cell types. 
For example, CD4+ T cells express equivalent levels of IĸBα and IĸBβ 
that are significantly higher than that of IĸBε, while IĸBε is by far the 
pre-dominant IĸB protein in naïve B cells which express relatively low 
levels of IĸBα. In myeloid DCs IĸBε is also the pre-dominant IĸB protein, 
while monocytes express equivalent levels of all three IĸB proteins 
(Fig. 3C). The potential importance of different IĸB proteins in different 
cells is not clear, but the patterns identified here suggest cell specific 
roles for individual IĸB proteins. 
The NF-ĸB precursor proteins p105 and p100 also function as cyto-
plasmic IĸB proteins by binding NF-ĸB subunits through their C terminal 
ankyrin repeat domains [4]. The exact levels of precursor proteins and 
processed subunits cannot be directly determined from the available 
Fig. 3. Cell type specific patterns of IĸB protein levels at the steady state. (A) Distribution of IĸBα, IĸBβ and IĸBε protein abundance across all cell types at the 
steady state. Mean values of replicate samples for each cell type are plotted. Violin plot shows upper and lower quartiles (dotted lines) and the median (solid line). (B) 
Combined copy numbers of IĸBα, IĸBβ and IĸBε for all cell types at the steady state. Violin plots shows mean value for each cell type, upper and lower quartiles 
(dotted lines) and the median (solid line). (C) Copy number per cell at the steady state of IKKα, IKKβ and NEMO for CD4+ T cells, CD8+ T cells, naïve B cells, and 
myeloid DCs (mDCs). Individual replicate values are shown, mean value is indicated by solid line, boxes extend from the upper to lower quartile and whiskers 
indicate minimum and maximum values. (D) Distribution of p105 and p100 estimated protein abundance across all cell types at the steady state. Mean values of 
replicate samples for each cell type are plotted. Violin plot shows upper and lower quartiles (dotted lines) and the median (solid line). (E) Copy number per cell of 
BCL-3 and (F) IĸBζ for individual cell types. For (E) and (F) individual replicate values are shown, median value is indicated by solid line, boxes extend from the 
upper to lower quartile and whiskers indicate minimum and maximum values. Cell types where protein is present (p < 0.05) are indicated by *. CD4, CD4+ T cells; 
CD4 CM, CD4+ central memory T cells; CD4 EM, CD4+ effector memory T cells; CD4 EMRA, CD4+CD45+ effector memory T cells; CD8, CD8+ T cells; T reg, 
regulatory T cells; NK bright, natural killer cells CD56high; NK dim, natural killer cells CD56low; MO classical, monocytes CD14+CD16− ; MO intermediate, monocytes 
CD14+CD16low; MO non-classical, monocytes CD14+CD16+; mDC, myeloid dendritic cells; pDCs, plasmacytoid dendritic cells. 
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proteomic data since this data comprises peptides originating from the 
processed subunits p50 and p52 as well as p105 and p100. However, 
assuming that all NF-ĸB dimers are bound to a single IĸB and are thereby 
inactive in the steady state, we calculated the levels of p105 and p100 
using the protein levels of the NF-ĸB subunits (see next section). This 
suggests that p105 is the most abundant IĸB protein in all cell types, with 
an average abundance greater than that of the other IĸBs combined, 
while on average p100 levels are closer to those of IĸBε (Fig. 3D). 
The atypical IĸB proteins BCL-3, IĸBζ, IĸBNS and IĸBη have been 
reported previously to be expressed at low levels in resting cells. The 
proteomic data analysed here supports these findings and shows that the 
expression levels of these factors in most cells is below the limit of 
detection. Significant levels of IĸBNS or IĸBη above the detection 
threshold were not found in any of the cells types analysed (data not 
shown) while BCL-3 protein is detected in T regulatory cells, basophils, 
myeloid and plasmacytoid dendritic cells and NK cells (Fig. 3E). IĸBζ 
was expression was detected in CD4+ effector memory cells, naïve B 
cells, and intermediate and non-classical monocytes (Fig. 3F). This in-
dicates that, at least in resting cells, the atypical proteins may have non- 
redundant, cell type specific roles. Of course, it is to be noted that levels 
of proteins below the threshold for detection does not mean these factors 
are absent but it does re-enforce that these factors are present in very 
low levels in resting cells. 
3.3. The abundance of the NF-ĸB subunits RelB and cRel varies widely 
across cell types 
The five subunits of the NF-ĸB family are generally considered to be 
ubiquitously expressed. Analysis of immune cell data supports this and 
shows that all five NF-ĸB subunits are detected in all cell types (Fig. 4A). 
The average total number of NF-ĸB subunits per cell ranged from 1.2 ×
106 in neutrophils to 3.4 × 105 in naïve B cells with an average of 5.9 ×
105 per cell across all cell types (Fig. 4B). The relative protein levels of 
each subunit varies within a given cell type, however NFKB1 (p105/ 
p50) is the most abundant NF-ĸB subunit in most cell types at the steady 
state (Fig. 4A and C). RelA, NFKB1 and NFKB2 (p100/p52) show rela-
tively low variation in abundance between different cell types in 
contrast to RelB and cRel which vary widely in abundance across cell 
types. RelB is the least abundant subunit in all cell types at the steady 
state with the exception of neutrophils (Fig. 4C) There appears to be an 
Fig. 4. Abundancies of NF-ĸB subunits in different cell types. (A) Distribution of RelA, NFKB1, cRel, NFKB2 and RelB protein abundance across all cell types at 
the steady state. Mean values of replicate samples for each cell type are plotted. Violin plot shows upper and lower quartiles (dotted lines) and the median (solid line). 
(B) Combined copy numbers of all subunits for all cell types at the steady state. Violin plots shows mean value for each cell type, upper and lower quartiles (dotted 
lines) and the median (solid line). (C) Hierarchical clustering of the relative levels of NF-ĸB subunits in individual cell types at steady state using the mean value of 
replicate samples for each cell type. Heat map presents relative minimum and maximum levels per row. (D) Copy number per cell at the steady state of each subunit 
for CD4 T cells, naïve B cells, classical monocytes and myeloid DCs (mDC). Individual replicate values are shown, mean value is indicated by solid line, boxes extend 
from the upper to lower quartile and whiskers indicate minimum and maximum values. CD4, CD4+ T cells; CD4 CM, CD4+ central memory T cells; CD4 EM, CD4+
effector memory T cells; CD4 EMRA, CD4+CD45+ effector memory T cells; CD8, CD8+ T cells; T reg, regulatory T cells; NK bright, natural killer cells CD56high; NK 
dim, natural killer cells CD56low; MO classical, monocytes CD14+CD16− ; MO intermediate, monocytes CD14+CD16low; MO non-classical, monocytes CD14+CD16+; 
mDC, myeloid dendritic cells; pDCs, plasmacytoid dendritic cells. 
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inverse relationship between the levels of cRel and NFKB2 protein 
(Fig. 4C); for example, the relative abundance of NFKB2 protein is 
highest in T lymphocytes such as CD4+ T cells where relative levels of 
cRel protein are low (Fig. 4C and D), while the highest relative abun-
dance of cRel is found in myeloid cells such as monocytes where the 
relative abundance of NFKB2 is low (Fig. 4C and D). 
3.4. A network model of the NF-ĸB pathway in steady state and activated 
cells 
We next constructed a network model of the NF-ĸB pathway using 
the average abundance of each component across all cell types. This 
revealed a remarkable conservation of stoichiometry of NF-ĸB pathway 
components across different cell types with relatively low variation in 
copy number per cell between different cell types at the steady state for 
most components (Fig. 5A). The factors with the most variable expres-
sion levels between cell types are IĸBα, IĸBε, RelB and cRel (Fig. 5A, 
Fig. 3A and Fig. 4A). This model also highlights the low levels of IĸB 
proteins (IĸBα, IĸBβ and IĸBε) relative to NF-ĸB subunits, further indi-
cating that the p105 protein is the major IĸB protein. The conserved NF- 
ĸB pathway structure in primary human immune cells is distinct from 
that observed in cell lines such as HeLa, HEK293, Jurkat and U2OS using 
similar quantitative proteomic data [12,13] (Supplementary Figs. 3–6). 
This is perhaps unsurprising considering the transformed nature of these 
cell lines, but it may have implications for the relevance of data from 
these cell systems to primary immune cells. We also utilised a recent 
study of mouse CD4+ and CD8+ T cells [14] to compare NF-κB networks 
between mouse and human T cells. This comparison reveals that overall 
the structure of the NF-κB pathway is highly similar between mouse and 
human cells, in particular the stoichiometry of the IKK complex com-
ponents, and the relative abundancies of IκBα, IκBβ and IκBε (Supple-
mentary Fig. 7). There is however a clear difference in the relative 
abundancies of RelA and NFKB1 between mouse and human cells. In 
mouse CD4+ and CD8+ cells RelA is the most abundant component of the 
NF-κB pathway and is 2–3 fold more abundant than NFKB1, while in 
human CD4+ and CD8+ T cells NFKB1 is the most abundant component 
Fig. 5. NF-ĸB pathway network in steady 
state and activated cells. Mean copy 
number per cell of each factor from replicate 
samples for each cell type were used to 
calculate mean values for each factor in the 
network in the (A) steady state and (B) 
activated state.. The size of each node is 
directly proportional to the mean protein 
abundance. The node colour reflects the 
calculated coefficient of variation (%CV) of 
each factor. Interactions are indicated by 
black lines; phosphorylation by dashed pur-
ple lines; and inhibition by blue lines. (For 
interpretation of the references to colour in 
this figure legend, the reader is referred to 
the web version of this article.)   
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and is approximately 2 fold more abundant than RelA. 
We next generated a network model using data from activated cells 
(CD4, CD4 CM, CD4 EM, CD4 EMRA, CD8, T reg, naïve B cells, memory 
B cell, monocytes, pDC, mDC and NK cells). This revealed that across all 
cell types the abundances of the IKK complex, RelA and IĸBβ are not 
substantially altered following activation (Fig. 5B). However, there is a 
remarkable activation-induced increase in the protein levels of NFKB2 
and RelB that is consistent across different cell types (Fig. 5B and 6A). 
There is also an increase in p105 protein expression in most activated 
cell types while increases in cRel and IĸBε protein levels occur in specific 
cell types following activation (Fig. 5B and 6A). Most cells types show 
significant increases in RelB after activation, with the exception of NK 
and T reg cells (Fig. 6A). Monocytes show the greatest increase in NFKB2 
levels following activation with approximately 110 fold more NFKB2 
protein per cell compared to the steady state, while in the same cells 
RelB protein levels are increased by 10 fold (Fig. 6B). Activated CD4+ T 
cells show a robust 14 fold increase in RelB protein levels compared to 
steady state cells, and a more modest 2 fold increase in NFKB2 protein 
relative to the steady state (Fig. 6B). As expected [19], activated CD4+ T 
cells have increased cRel protein levels compared to steady state cells. 
The approximately 3 fold increase in cRel protein in CD4+ T cells is 
similar to that seen in mDCs but lower than the 8 fold increase of cRel in 
activated naïve B cells (Fig. 6B). We confirmed the patterns of NF-κB 
subunits expression in steady state and LPS stimulated primary mono-
cytes using western blot approaches (Fig. 6C and D). Overall, this 
analysis reveals that the NF-ĸB pathway in activated cells is distinct from 
the steady state and that differences occur in a cell type specific manner. 
3.5. Distinct profiles of IĸB proteins in activated cells 
The activation induced degradation and re-synthesis of IĸB proteins 
is a critical regulatory feature of the NF-ĸB pathway [4]. Analysis of 
IĸBα, IĸBβ and IĸBε protein levels across all cell types in the resting and 
activated states reveals that the total copy number per cell of typical IĸB 
proteins is not significantly altered following activation (Fig. 7A). This 
also holds true for individual cell types with the exception of naïve and 
memory B cells, which demonstrate increased levels of IĸB proteins 
following activation (Fig. 7B). Of note, it is pre-dominantly the increased 
expression of IĸBε in activated B cells that accounts for the observed 
increase in IĸBε in the NF-ĸB network model of activated cells above 
(Fig. 5B). While the total number of IĸB proteins remains the same in 
activated cells relative to the steady state, activation appear to alter the 
relative abundancies of each IĸB protein in some cells. For example, 
mDCs and pDCs have reduced levels of IĸBβ but increased levels of IĸBα 
following activation (Fig. 7C and D). 
As previously noted, the atypical IĸB proteins BCL-3, IĸBζ and IĸBNS 
are absent or expressed at very low levels in cells at the steady state [4] 
(Fig. 3). Activation increases the expression of these proteins in a cell 
type specific manner(Fig. 8A). BCL-3 is the most abundant atypical IĸB 
protein in both the steady state (Fig. 3E) and activated cells, with a 
particularly high expression levels in activated mDCs (Fig. 8B). Of note, 
activation of mDCs also induces a significant increase in IĸBζ and IĸBNS 
protein levels, suggesting that the atypical IĸB proteins may play an 
important role in regulating NF-ĸB activity these cells (Fig. 8B). IĸBNS is 
not observed in activated cells other than mDCs while IĸBζ protein is 
also significantly increased in activated memory and naïve B cells. IĸBη 
is not detected in any cells following activation (data not shown). These 
analyses indicate that individual atypical IĸB proteins may have cell 
type specific roles following activation. 
To provide a further comparison of the overall structure of the NF-ĸB 
pathway in resting and activated cells we next generated a similarity 
matrix based on average protein copy number per cell of all factors 
across all cell types. This analysis revealed that the core NF-ĸB compo-
nents in the steady state are the IKK complex, IĸBα, IĸBβ, IĸBε, RelA, 
NFKB1 and cRel (Fig. 9), essentially comprising the classical NF-κB 
pathway. However, in activated cells the atypical IĸB proteins BCL-3, 
IĸBζ and IĸBNS replace IĸBα, IĸBβ and IĸBε in the similarity matrix 
(Fig. 9). This further supports the concept that the atypical IĸBs are 
important modifiers of NF-ĸB activity following activation. In addition, 
the RelB and NFKB2 subunits join the other subunits as part of the core 
NF-κB pathway in activated cells, reflecting the increased levels of these 
factors in activated cells. 
Fig. 6. Activation induces changes in NF-ĸB subunit levels. (A) NF-ĸB subunit levels in steady state versus activated cells. Scatter plot shows mean copy number 
of replicate samples for steady state versus activated state for each cell type. (B) Copy number per cell of each subunit at the steady state (− ) and activated state (+) 
for CD4 T cells, naïve B cells, classical monocytes and myeloid DCs (mDC). Individual replicate values are shown, mean value is indicated by solid line, boxes extend 
from the upper to lower quartile and whiskers indicate minimum and maximum values. (C) Western blot analysis of NF-κB subunits in primary human monocytes at 
the steady state and following activation (LPS treatment). Cells were lysed and western blot performed using the antibodies indicated. Tubulin expression was used as 
a loading control. CD4, CD4+ T cells; CD4 CM, CD4+ central memory T cells; CD4 EM, CD4+ effector memory T cells; CD4 EMRA, CD4+CD45+ effector memory T 
cells; CD8, CD8+ T cells; T reg, regulatory T cells; NK bright, natural killer cells CD56high; NK dim, natural killer cells CD56low; MO classical, monocytes 
CD14+CD16− ; MO intermediate, monocytes CD14+CD16low; MO non-classical, monocytes CD14+CD16+; mDC, myeloid dendritic cells; pDCs, plasmacytoid den-
dritic cells. 
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4. Discussion 
Quantitative proteomic data offer a unique opportunity to assess the 
current model of the NF-ĸB pathway. In this study we have used open 
access data from primary human immune cells in the steady and acti-
vated states to measure the abundance and stoichiometry of the core 
components of the pathway. Overall the analysis shows a strong con-
servation of pathway structure across different cell types and lineages. 
The analysis also reveals that the structure of the NF-ĸB pathway is 
dynamic in response to activating stimuli and that increased RelB and 
NFKB2 protein levels is a general feature of activated immune cells. The 
majority of the core pathway components are present in highly similar 
abundancies in different cell types, revealing that the NF-ĸB pathway in 
different cell types is broadly the same in terms of structure and abun-
dance. An exception to this is the low abundance of NF-κB pathway 
components in T regulatory cells, an observation which correlates 
strongly with the requirement for these cells to supress NF-κB activity to 
maintain function [20]. 
While the broad similarity of the NF-κB structure in primary immune 
cells will allow for the extrapolation of observations in one cell type to 
another, the obvious dissimilarity to cells commonly used to study NF- 
ĸB suggests caution in extrapolating findings from cell lines to primary 
cells. This is clearly illustrated when considering the stoichiometry of 
the IKK complex which is widely accepted to be composed of equal 
amounts of IKKα and IKKβ, with a number of different stoichiometries 
proposed including IKKα1:IKKβ1:NEMO2. However, assuming that there 
is no free pool of these proteins outside the IKK complex, the analysis 
here indicates a stoichiometry of (IKKα/β)2:NEMO1. Moreover, in 
contrast to cell lines such as HeLa, the relative excess of IKKβ over IKKα 
in primary cells indicates that the majority of IKK complexes are likely 
composed of IKKβ homodimers. Indeed, in some cell types such as CD4+
T cells, the excess of IKKβ over IKKα suggests the possibility that the IKK 
complex is composed exclusively of IKKβ and NEMO, since NEMO does 
not directly bind IKKα [5]. It is not known whether the functional 
properties of IKK complexes composed of IKKβ homodimers are different 
to those composed of IKKα and IKKβ heterodimers but it is worthy of 
investigation. 
The non-canonical pathway of NF-ĸB activation has been predomi-
nantly linked to a relatively small number of TNFR superfamily mem-
bers including CD40, RANK, Lymphotoxin β receptor and BAFF receptor 
[6]. It requires IKKα, but not IKKβ nor NEMO, and involves the activa-
tion of NF-ĸB dimers composed of RelB and p52 [7]. From the analysis 
here we see that RelB is the least abundant subunit in almost all cell 
types at the steady state indicating a potentially limited role for the non- 
canonical pathway. However, in activated cells there is a significant 
increase in the abundance of RelB and NFKB2 in most cells, indicating 
that the non-canonical pathway may play an important role in immune 
cells post activation and may indeed be a general feature of activated 
Fig. 7. Cell type specific changes in IĸB protein abundance following activation. (A) Copy number per cell of IĸBα, IĸBβ and IĸBε for each cell type in the steady 
state and activated state. Graphs show the mean of individual replicate samples +/− SEM. (B) Combined copy number per cell of IĸBα, IĸBβ and IĸBε for cells in the 
steady state and activated state. Violin plots show mean values of replicate samples for each cell type, the median (solid line) and the upper and lower quartiles 
(dotted line). (C) Combined copy number per cell of IĸBα, IĸBβ and IĸBε in steady state versus activated cells. Scatter plot shows mean copy number of replicate 
samples for steady state versus activated state for each cell type. * p < 0.05, ** p < 0.003. (D) Hierarchical clustering of the relative levels of IĸB proteins in individual 
cell types at steady state and activated state using the mean value of replicate samples for each cell type. Heat map presents relative minimum and maximum levels 
per row. CD4, CD4+ T cells; CD4 CM, CD4+ central memory T cells; CD4 EM, CD4+ effector memory T cells; CD4 EMRA, CD4+CD45+ effector memory T cells; CD8, 
CD8+ T cells; T reg, regulatory T cells; NK bright, natural killer cells CD56high; NK dim, natural killer cells CD56low; MO classical, monocytes CD14+CD16− ; MO 
intermediate, monocytes CD14+CD16low; MO non-classical, monocytes CD14+CD16+; mDC, myeloid dendritic cells; pDCs, plasmacytoid dendritic cells. 
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immune cells, independent of the activating stimulus. The established 
role of the non-canonical pathway in controlling B cell homeostasis in 
the periphery [21] and T cell memory [22] suggests that this pathway 
may be broadly important in deciding the cell fate of most immune cells 
following stimulation. 
IĸBα is the prototypic member of the IĸB family of proteins and its 
deletion in mice results in death shortly after birth [23]. However, the 
analysis here reveals that IĸBβ is more abundant than IκBα in the ma-
jority of cells at the steady state with IĸBε predominant in naïve B cells 
and mDCs. The roles of IĸBβ and IĸBε in regulating the NF-ĸB are less 
well understood although the available data suggests that they have 
distinct properties to IĸBα. IĸBβ plays a role in promoting the duration of 
NF-ĸB transcriptional activity on certain genes such as IL-1β [24,25] and 
may also be important in the generation of RelA homodimers [26], while 
the delayed kinetics of IKK induced degradation of IĸBε may play a role 
in shaping the duration of NF-ĸB activity [27,28]. Understanding the 
biological roles of IĸB proteins is complicated by functional redundancy 
in vivo [29] and the importance of feedback loops in the NF-ĸB pathway 
in setting protein levels [30]. However, the significant amounts of IĸBβ 
and IĸBε in primary immune cells suggests that the contribution of these 
factors to the NF-ĸB pathway may not be fully appreciated. The low 
abundancies of IκBα, β and ε proteins relative to RelA are surprising, as is 
the relatively low abundance of IκBα in most cells, particularly when 
considering the key role played by IκBα in regulating NF-κB activity. 
Conversely, NFKB1 constitutes the most abundant component of the NF- 
κB pathway but Nfkb1 deletion in mice leads to a relatively moderate 
immune phenotype when compared to deletion of Nfkbia [3]. How IκBα 
achieves it’s regulatory power over NF-κB activity while present at such 
relatively low abundance is unclear. Analysis of a recent dataset 
generated from mouse CD4+ and CD8+ T cells [14] reveals that the 
structure of the NF-κB pathway is highly similar between mouse and 
human for these cell types with one notable exception. In mouse CD4+
and CD8+ cells RelA is the most abundant component of the NF-κB 
pathway while in human CD4+ and CD8+ T cells NFKB1 is the most 
Fig. 8. Cell type specific changes in atypical IĸB protein abundance following activation. (A) Combined copy numbers per cell of IĸBα, IĸBβ and IĸBε for cells 
in the steady and activated state. Violin plots show mean values of replicate samples for each cell type, the median (solid line) and the upper and lower quartiles 
(dotted line). Only data from cell types expressing at least one protein in at least one state is shown. (B) Copy number per cell of BCL-3, IĸBζ and IĸBNS for each cell 
type in the steady state and activated state. Graphs show the mean of individual replicate samples +/− SEM. * p < 0.05, ** p < 0.003, *** p < 0.001. (C) Hierarchical 
clustering of the relative levels of IĸB proteins in individual cell types at steady state and activated state using the mean value of replicate samples for each cell type. 
Heat map presents relative minimum and maximum levels per row. Grey colour indicates that no expression was detected. CD4, CD4+ T cells; CD4 CM, CD4+ central 
memory T cells; CD4 EM,CD4+ effector memory T cells; CD4 EMRA, CD4+CD45+ effector memory T cells; CD8, CD8+ T cells; T reg, regulatory T cells; NK bright, 
natural killer cells CD56high; NK dim, natural killer cells CD56low; MO classical, monocytes CD14+CD16− ; MO intermediate, monocytes CD14+CD16low; MO non- 
classical, monocytes CD14+CD16+; mDC, myeloid dendritic cells; pDCs, plasmacytoid dendritic cells. 
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abundant component. It is noteworthy that Nfkb1+\- mice do not have an 
overt immune phenotype [31] while NFKB1 haploinsufficiency is the 
most common monogenic cause of combined variable immunodefi-
ciency in Europeans [32]. Thus, it is tempting to speculate that the 
greater relative abundance of NFKB1 in human cells may underlie its 
greater importance in humans compared to mouse. 
The atypical IĸB proteins BCL-3, IĸBζ, IĸBNS and IĸBη are located 
predominantly in the nucleus where they act to modulate the activity of 
specific NF-ĸB dimers [3]. Previous reports that these proteins are 
mostly expressed a low levels at the steady state but induced following 
activation are reflected in the analysis presented here [33–36]. IĸBη was 
not detected in any of the data analysed here indicting that it may not be 
a significant regulator of NF-ĸB in immune cells. As with the typical IĸB 
proteins, the expression profiles of atypical IĸBs are cell type specific 
with BCL-3 being the most abundant and most widely expressed. The 
functional impact of these different profiles on NF-ĸB activity is unclear 
and additional experimental investigation will be needed to provide 
greater understanding. 
An overview of the patterns of abundance between the components 
of the NF-ĸB pathway in all cell types identifies the core pathway 
components in both the steady and activated states. Unsurprisingly, the 
IKK complex, the canonical subunits RelA, NFKB1 and cRel, and the IĸB 
members IĸBα, IĸBβ and IĸBε form the core in the steady state. In the 
activated state the core components of the pathway are different and 
includes all the NF-ĸB subunits including NFKB2 and RelB and the 
atypical IĸB proteins BCL-3, IĸBζ and IĸBNS, reflecting changes in the 
abundance of RelB, NFKB2 and the atypical IĸB proteins. This analysis 
raises important questions when considering how the NF-ĸB pathway 
may be exploited for therapeutic benefit. To date, the key strategy for 
preventing NF-ĸB dependent inflammation has been to inhibit the IKK 
complex using IKKβ kinase inhibitors, which unfortunately leads to se-
vere toxicity that precludes their clinical application [37]. However, if 
we consider that activated cells, rather than cells in the steady state, are 
the key contributors to inflammatory disease then the differences in the 
architecture of the NF-ĸB pathway between these two states may point 
towards alternative strategies. The almost universal increase in RelB and 
NFKB2 abundance in immune cells activated by diverse stimuli suggests 
that the non-canonical pathway may be a more effective target. The 
recent development of IKKα specific kinase inhibitors may allow for the 
selective modulation of activated cells over those in the steady state 
[38]. Such an approach necessitates a clear understanding of the role of 
the non-canonical pathway in activated immune cells and the conse-
quences of its blockade. Similarly, the expression of atypical IĸB proteins 
in activated cells in cell type specific patterns identifies these as factors 
that distinguish between immune cells in the activated and steady states. 
While these factors make difficult drug targets, proof of principle ex-
periments have shown that BCL-3 mimetic peptides are effective at 
inhibiting pro-inflammatory cytokine production in vitro and in vivo 
[39]. 
In summary, quantitative proteomic analysis offers unique insights 
into the structure of the NF-ĸB pathway in primary cells which differs in 
important ways from those of cell lines commonly used in its study. It 
raises important questions on the nature of the IKK complex and the role 
of individual IĸB proteins that require further experimental investiga-
tion in order to answer. Moreover, it shows that the structure of the NF- 
ĸB pathway is dynamic following cellular activation suggesting new 
approaches to harnessing this pathway for therapeutic benefit. 
Declaration of Competing Interest 
The authors have no conflict of interest. 
Acknowledgements 
This work was supported by the Medical Research Council (MR/ 
M010694/1) and the Biotechnology and Biological Sciences Research 
Council (BB/M003671/1 and BB/T007427/1). 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
Fig. 9. Distinct NF-ĸB architecture in steady stated and activated cells. 
Mean copy numbers of each factor per cell for all cell types were used to 
generate a similarity matrix based on relative abundances. Cells at the steady 
state have similar patterns of expression for IKKα, IKKβ, NEMO, the IĸB proteins 
α, β and ε, and the NF-ĸB subunits RelA, p105 and cRel. Following activation 
cells share similar patterns of expression of all NF-ĸB subunits and the atypical 
IĸB proteins BCL-3, IĸBζ and IĸBNS. 
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